m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05097
 [1]
Non-coding RNA miR-155 HIF1A  lncRNA       miRNA   circRNA Indirect Inhibition m6A modification SOX2 SOX2 ALKBH5 Demethylation : m6A sites
m6A Modification:
m6A Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
m6A Target Transcription factor SOX-2 (SOX2)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator MicroRNA 155 (MIR155) microRNA View Details
Regulated Target Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary Inhibition of MIR155 promoted the expression of Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A) and attenuated the m6A modification of Transcription factor SOX-2 (SOX2) mRNA by regulating ALKBH5, thereby promoting the expression of SOX2 and activating the downstream EGFR/MEK/ERK signaling pathway to promote wound healing in an in vitro DFU model.
Responsed Disease Diabetic foot ulcers ICD-11: BD54
 Disease Info 
In-vitro Model
 HaCaT Normal Homo sapiens CVCL_0038
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A) 21 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PT2385 Phase 2 [2]
Synonyms
ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 91754484
TTD: D0C9PZ
 Compound Name ISIS 298697 Investigative [3]
External Link
TTD: D00JHE
 Compound Name ISIS 298744 Investigative [3]
External Link
TTD: D01DDQ
 Compound Name ISIS 298746 Investigative [3]
External Link
TTD: D01ZCK
 Compound Name ISIS 298745 Investigative [3]
External Link
TTD: D07GVC
 Compound Name ISIS 298743 Investigative [3]
External Link
TTD: D09DCJ
 Compound Name ISIS 298702 Investigative [3]
External Link
TTD: D0B5LQ
 Compound Name ISIS 298700 Investigative [3]
External Link
TTD: D0C2IG
 Compound Name ISIS 175510 Investigative [3]
External Link
TTD: D0G9BP
 Compound Name ISIS 298699 Investigative [3]
External Link
TTD: D0L5ME
 Compound Name ISIS 298712 Investigative [3]
External Link
TTD: D0L9KW
 Compound Name ISIS 298711 Investigative [3]
External Link
TTD: D0SN5O
 Compound Name ISIS 298701 Investigative [3]
External Link
TTD: D0X8GB
 Compound Name (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol Investigative [4]
Synonyms
Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5712
TTD: D00REK
 Compound Name HIF-1alpha Phase 4 [5]
Synonyms
Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060
    Click to Show/Hide
External Link
CID: 5328127
TTD: D0B0AX
 Compound Name IT-101 Phase 3 [5]
External Link
TTD: D06PEW
 Compound Name 2-Methoxyestradiol Phase 2 [5]
Synonyms
ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene
    Click to Show/Hide
External Link
CID: 66414
TTD: D06NYA
DrugBank: DB02342
 Compound Name PX-478 Phase 1 [5]
Synonyms
685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di
    Click to Show/Hide
External Link
CID: 11234794
TTD: D06ZVO
DrugBank: DB06082
 Compound Name EZN-2968 Phase 1 [5]
External Link
TTD: D0NF5J
 Compound Name ENMD-1198 Phase 1 [5]
Synonyms
EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed
    Click to Show/Hide
External Link
CID: 11483754
TTD: D0Y5QD
DrugBank: DB05959
 Compound Name Pyrrolidine carboxamide derivative 1 Patented [5]
Synonyms
PMID26882240-Compound-22
    Click to Show/Hide
External Link
CID: 56684144
TTD: D0Q2SE
BD54: Diabetic foot ulcers 47 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Pexiganan Approved [6]
Synonyms
UNII-TVF29Q70Q1; TVF29Q70Q1; Pexiganan [INN]; 147664-63-9; SCHEMBL476400; CHEMBL1275802; Glycyl-L-isoleucylglycyl-L-lysyl-L-phenylalanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-lysyl-L-lysyl-L-phenylalanylglycyl-L-lysyl-L-alanyl-L-phenylalanyl-L-valyl-L-lysyl-L-isoleucyl-L-leucyl-L-lysyl-L-lysinamide; Magainin I, 7-L-lysine-8-L-lysine-10-L-lysine-18-L-lysine-19-de-L-glutamic acid-21-L-leucine-23-L-lysinamide; L-Lysinamide, glycyl-L-isoleucylglycyl-L-lysyl-L-phenylalanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-lys
    Click to Show/Hide
External Link
CID: 16132253
TTD: D0Y9GM
 Compound Name CT-102 Approved [7]
External Link
TTD: D0U5SC
 Compound Name Doxycycline Phase 2 [8]
Synonyms
Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline
    Click to Show/Hide
External Link
CID: 54671203
TTD: D0S0LZ
DrugBank: DB00254
 Compound Name Nemonoxacin Phase 3 [9]
Synonyms
378746-64-6; UNII-P94L0PVO94; TG-873870; P94L0PVO94; Nemonoxacin [INN]; 7-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-[(3S,5S)-3-Amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; SCHEMBL1006373; CHEMBL1213456; CHEBI:136053; ZINC40435195; SB16570; FT-0700967; 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- oxo-1,4-dihydroquinoline-3-carboxylic acid
    Click to Show/Hide
External Link
CID: 11993740
TTD: D0P0RX
DrugBank: DB06600
 Compound Name Alprostadil Approved [7]
Synonyms
Prostaglandin E1; 745-65-3; PGE1; Muse; Edex; Caverject; Prostin VR; Alprostadilum; Femprox; Befar; Vitaros; Prostandin; Liprostin; PGE-1; Prink (TN); Befar (TN); Prostavasin; Vasaprostan; MR-256; Minprog; UNII-F5TD010360; Alprostadil(Caverject); CHEMBL495; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Prostivas; Lipoprost; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; FemLife; RayVa; Sugiran; Viridal; MR 256; PGE1 Oligomer; BML1-F06; Caverject (TN); Edex (TN); HEI-507; Muse (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Lipo-alprostadil
    Click to Show/Hide
External Link
CID: 5280723
TTD: D0I4DQ
DrugBank: DB00770
 Compound Name Daprodustat Phase 1 [10]
Synonyms
Daprodustat; 960539-70-2; UNII-JVR38ZM64B; GSK-1278863; JVR38ZM64B; N-((1,3-Dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl)glycine; Daprodustat [USAN:INN]; GSK 1278863; Daprodustat(GSK1278863); Daprodustat (JAN/USAN/INN); GTPL8455; Daprodustat (GSK1278863); CHEMBL3544988; KS-00000M8Z; EX-A1121; BCP16766; s8171; AKOS027439964; Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-; ZINC231226004; CS-5453; SB19761; DB11682; HY-17608; J3.560.573H; D10874
    Click to Show/Hide
External Link
CID: 91617630
TTD: D0F6JC
DrugBank: DB11682
 Compound Name Prezatide copper acetate Approved [6]
Synonyms
Iamin gel (TN)
    Click to Show/Hide
External Link
CID: 3086626
TTD: D0C3LP
 Compound Name Nitroglycerin Approved [7]
Synonyms
Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401
    Click to Show/Hide
External Link
CID: 4510
TTD: D07YDE
DrugBank: DB00727
 Compound Name Apligraf Approved [6]
Synonyms
Graftskin
    Click to Show/Hide
External Link
TTD: D07XCG
 Compound Name HEGF Approved [7]
External Link
TTD: D05GGP
 Compound Name Donaperminogene seltoplasmid Phase 3 [11]
Synonyms
VM202
    Click to Show/Hide
External Link
TTD: D9CI7V
 Compound Name ALLO-ASC-DFU Phase 3 [12]
External Link
TTD: D5JVD6
 Compound Name Granexin Phase 3 [13]
External Link
TTD: D4MO2K
 Compound Name White blood cell therapy Phase 3 [14]
External Link
TTD: D0Q9TB
 Compound Name ICX-PRO Phase 3 [15]
Synonyms
Cyzact; ProtoDerm; ICXP-007; Allogeneic human dermal fibroblasts (wound healing), Healthpoint; Allogeneic human dermal fibroblasts (wound healing), Intercytex
    Click to Show/Hide
External Link
TTD: D0O1UT
 Compound Name CureXcell Phase 3 [16]
External Link
TTD: D0N1YG
 Compound Name INL-002 Phase 3 [10]
External Link
TTD: D0K4GW
 Compound Name Talactoferrin Phase 3 [17]
Synonyms
Talactoferrin (topical)
    Click to Show/Hide
External Link
TTD: D0IM6O
 Compound Name VM-202 Phase 3 [18]
External Link
TTD: D0D4OS
 Compound Name Ch14.18 mab Phase 3 [19]
External Link
TTD: D07VKT
 Compound Name PDGF-BB Phase 3 [20]
Synonyms
PDGF-BB (BioChaperone technology, diabetic foot ulcer/venous ulcers/burns)
    Click to Show/Hide
External Link
TTD: D04BVN
 Compound Name DSC-127 Phase 3 [21]
Synonyms
aclerastide; UNII-YYD6UT8T47; YYD6UT8T47; Aclerastide [INN]; Norleu3-a(1-7); Asp-arg-nle-tyr-ile-his-pro; DSC127; USB-001; 227803-63-6; 1-7-Angiotensin II, 3-L-norleucine-5-L-isoleucine
    Click to Show/Hide
External Link
CID: 9811551
TTD: D01TEA
DrugBank: DB12631
 Compound Name Granexin gel Phase 3 [18]
Synonyms
alphaCT1
    Click to Show/Hide
External Link
TTD: D01NWV
 Compound Name Dermacyn Phase 2 [22]
External Link
TTD: D0VW0A
 Compound Name MBN-101 Phase 2 [23]
External Link
TTD: D0UC5G
 Compound Name ACT-1 Phase 2 [24]
External Link
TTD: D0Q4WG
 Compound Name CVBT-141B Phase 2 [10]
External Link
TTD: D0Q3ER
 Compound Name IL22-Fc Phase 2 [18]
External Link
TTD: D0Q1RN
 Compound Name HO/03/03 Phase 2 [25]
Synonyms
PKC modulator (topical peptide, DU/VU/PU), HealOr
    Click to Show/Hide
External Link
TTD: D0O3XU
 Compound Name RG7880 Phase 2 [26]
External Link
TTD: D0G5BL
 Compound Name GAM-501 Phase 2 [27]
Synonyms
Excellarate; Diabetic ulcer product, Selective Genetics; AdPDGF-B/GAM; Adenoviral gene therapy (PDGF-B), Selective Genetics; PDGF-B adenoviral gene therapy (collagen gel, diabetic foot ulcer), Tissue Repair Company
    Click to Show/Hide
External Link
TTD: D0A6WA
 Compound Name Nexagon Phase 2 [28]
External Link
TTD: D09BIX
 Compound Name MRE-0094 Phase 2 [7]
Synonyms
SCHEMBL13010610; MRE 0094
    Click to Show/Hide
External Link
CID: 9910098
TTD: D06MIQ
DrugBank: DB12443
 Compound Name CVBT-141B topical Phase 2 [18]
External Link
TTD: D06HMO
 Compound Name PDA-002 Phase 2 [10]
External Link
TTD: D04PVE
 Compound Name DCB-WH1 Phase 2 [29]
Synonyms
PAF4 + S1 (wound healing), Development Centre for Biotechnology; PAF4 + S1 (wound healing), Microbio
    Click to Show/Hide
External Link
TTD: D03VLG
 Compound Name Galnobax Phase 1/2 [10]
External Link
TTD: D0P5FA
 Compound Name Nu-3 Phase 1/2 [10]
External Link
TTD: D0LP2P
 Compound Name ATG002 Phase 1/2 [30]
External Link
TTD: D0E7MA
 Compound Name Nu-3 Phase 1/2 [18]
Synonyms
Topical Nubiotics (bacterial infection), Lakewood Amedex
    Click to Show/Hide
External Link
CID: 10279357
TTD: D03JDA
 Compound Name ExpressGraft Phase 1 [31]
External Link
TTD: D5H2SZ
 Compound Name BRX-005 Phase 1 [32]
Synonyms
Arimoclomol maleate; BRX-220; Bimoclomol derivatives, Biorex
    Click to Show/Hide
External Link
CID: 6421776
TTD: D09VWI
DrugBank: DB05444
 Compound Name WPP-201 Phase 1 [33]
External Link
TTD: D07XEV
 Compound Name Telbermin Discontinued in Phase 2 [7]
Synonyms
Telbermin (USAN/INN)
    Click to Show/Hide
External Link
TTD: D07HAD
 Compound Name Rusalatide acetate Discontinued in Phase 2 [34]
Synonyms
Chrysalin; TP508; Chrysalin (gel); TP-508; TP508 (gel); TRAP-508
    Click to Show/Hide
External Link
CID: 44149697
TTD: D01FEC
 Compound Name PLR-15 Terminated [35]
External Link
TTD: D0S2KX
 Compound Name PDGF gene therapy Investigative [7]
Synonyms
UNII-54FF09J702; 54FF09J702; Ancriviroc besylate; SCH-351125 Besylate; 565428-86-6; (1,4'-Bipiperidine)-4-methanimine, alpha-(4-bromophenyl)-1'-((2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl)-N-ethoxy-4'-methyl-, (alphaZ)-, benzenesulfonate
    Click to Show/Hide
External Link
CID: 9875058
TTD: D08NYO
References
Ref 1 miR-155 promotes m6A modification of SOX2 mRNA through targeted regulation of HIF-1alpha and delays wound healing in diabetic foot ulcer in vitro models. J Diabetes Investig. 2025 Jan;16(1):60-71. doi: 10.1111/jdi.14327. Epub 2024 Nov 7.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
Ref 4 Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6305-10. doi: 10.1016/j.bmcl.2007.09.005. Epub 2007 Sep 7.
Ref 5 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 7 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. doi: 10.1517/14728214.11.4.709.
Ref 8 ClinicalTrials.gov (NCT00764361) Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers. U.S. National Institutes of Health.
Ref 9 TaiGen Biotechnology Announces Submission of New Drug Application for Nemonoxacin in Taiwan and Mainland China. TaiGen Biotechnology Co., Ltd. May 16, 2013.
Ref 10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 11 ClinicalTrials.gov (NCT02563522) Safety and Efficacy Study of VM202 in the Treatment of Chronic Non-Healing Foot Ulcers. U.S. National Institutes of Health.
Ref 12 ClinicalTrials.gov (NCT04569409) Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.. U.S. National Institutes of Health.
Ref 13 ClinicalTrials.gov (NCT02667327) A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer. U.S. National Institutes of Health.
Ref 14 Clinical pipeline report, company report or official report of Macrocure.
Ref 15 ClinicalTrials.gov (NCT00232973) Safety and Efficacy Study of ICXP007 With Compression Bandaging for the Treatment of Non-Infected Venous Leg Ulcers. U.S. National Institutes of Health.
Ref 16 ClinicalTrials.gov (NCT02130310) Evaluation of CureXcell in Treating Chronic Venous Leg Ulcers. U.S. National Institutes of Health.
Ref 17 ClinicalTrials.gov (NCT00706862) Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 19 Clinical pipeline report, company report or official report of United Therapeutics.
Ref 20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5039).
Ref 21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8300).
Ref 22 ClinicalTrials.gov (NCT00516958) Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn Wound Care to Treat Mild Diabetic Foot Infections. U.S. National Institutes of Health.
Ref 23 ClinicalTrials.gov (NCT02436876) Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites. U.S. National Institutes of Health.
Ref 24 Clinical pipeline report, company report or official report of FirstString Research.
Ref 25 ClinicalTrials.gov (NCT00926068) Safety and Efficacy of HO/03/03 10 in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers. U.S. National Institutes of Health.
Ref 26 Clinical pipeline report, company report or official report of Roche.
Ref 27 ClinicalTrials.gov (NCT00493051) Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities. U.S. National Institutes of Health.
Ref 28 Clinical pipeline report, company report or official report of CoDa Therapeutics.
Ref 29 ClinicalTrials.gov (NCT00709514) Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers. U.S. National Institutes of Health.
Ref 30 ClinicalTrials.gov (NCT00316537) Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers. U.S. National Institutes of Health.
Ref 31 ClinicalTrials.gov (NCT04134143) An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft- C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers. U.S.National Institutes of Health.
Ref 32 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013054)
Ref 33 ClinicalTrials.gov (NCT00663091) A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers. U.S. National Institutes of Health.
Ref 34 Thrombin peptide TP508 accelerates closure of dermal excisions in animal tissue with surgically induced ischemia. Wound Repair Regen. 2000 Nov-Dec;8(6):517-29.
Ref 35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022815)